Alseres Pharmaceuticals, Inc.
ALSE · OTC
12/31/2013 | 12/31/2012 | 12/31/2011 | 12/31/2010 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $0 | $0 | $0 | $0 |
| Short-Term Investments | $0 | $1 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $0 | $0 | $0 | $0 |
| Total Curr. Assets | $0 | $1 | $0 | $0 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $0 | $0 | $0 | $0 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $0 | $1 | $0 | $0 |
| Liabilities | – | – | – | – |
| Payables | $1 | $2 | $0 | $4 |
| Short-Term Debt | $0 | $6 | $28 | $34 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $1 | $1 | $3 | $5 |
| Total Curr. Liab. | $2 | $10 | $30 | $42 |
| LT Debt | $8 | $0 | $0 | $0 |
| Deferred Rev, NC | $1 | $1 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $16 | $0 | $5 |
| Total NC Liab. | $9 | $18 | $0 | $5 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $11 | $28 | $31 | $48 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$200 | -$199 | -$197 | -$194 |
| AOCI | $0 | -$0 | -$0 | $0 |
| Other Equity | $189 | $172 | $167 | $147 |
| Total Equity | -$11 | -$27 | -$31 | -$47 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $0 | $1 | $0 | $0 |
| Net Debt | $8 | $6 | $28 | $34 |